RecruitingPhase 2NCT06136403

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Sponsor

Centre Hospitalier Universitaire de Nice

Enrollment

10 participants

Start Date

Mar 18, 2024

Study Type

INTERVENTIONAL

Conditions

Ichthyosis Epidermolysis Bullosa Simplex Genodermatosis Inflammatory Congenital Ichthyoses

Summary

The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria3

Subject has congenital skin fragility with skin and/or mucosal blisters, a clinical phenotype of EBS-sev and a laboratory confirmed diagnosis of EBS by KRT5 and/or 14 mutation (autosomal only) OR a clinical phenotype of inflammatory ichthyosis (IC) including keratinopathic ichthyosis due to KRT1/10 mutation, ECI with identified genetic mutations (TGM5, NIPAL4, ABCA12, etc…).
Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS > 50/128.
Subject agrees not to use any topical therapies other than the investigator approved.